Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rossing, K.
Right arrow Articles by Parving, H.-H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rossing, K.
Right arrow Articles by Parving, H.-H.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Diabetes Care 25:95-100, 2002
© 2002 by the American Diabetes Association, Inc.

Emerging Treatments and Technologies
Original Article

Dual Blockade of the Renin-Angiotensin System in Diabetic Nephropathy

A randomized double-blind crossover study

Kasper Rossing, MD, Per K. Christensen, MD, Berit R. Jensen and Hans-Henrik Parving, Prof., MD, DMSC

Steno Diabetes Center, Gentofte, Denmark

OBJECTIVE—Many patients with diabetic nephropathy (DN) have levels of albuminuria >1 g/day and blood pressure >135/85 mmHg, despite antihypertensive combination therapy, including recommended doses of ACE inhibitors, e.g., lisinopril/enalapril at 20 mg daily. We tested the concept that such patients might benefit from dual blockade of the renin-angiotensin system (RAS).

RESEARCH DESIGN AND METHODS—We performed a randomized double-blind crossover study of 2 months treatment with candesartan cilexetil 8 mg once daily and placebo in addition to previous antihypertensive treatment. We included 18 type 2 diabetic patients with DN fulfilling the above-mentioned criteria. All received recommended doses of ACE inhibitor and, in addition, 15 patients received diuretics, 11 received a calcium channel antagonist, and 3 received a ß-blocker. At the end of each treatment period, we measured the glomerular filtration rate (GFR), 24-h blood pressure, albuminuria, and IgGuria .

RESULTS—The addition of candesartan to usual antihypertensive therapy induced a mean (95% CI) reduction in albuminuria of 25% (2–58), P = 0.036 (geometric mean [95% CI] from 1,764 mg/24 h [1,225–2,540] to 1,334 mg/24 h [890–1,998]). It also produced a mean reduction of 35% (9–53) in the fractional clearance of albumin (P = 0.016), a reduction of 32% (1–54) in fractional clearance of IgG (P = 0.046), a reduction in 24-h systolic blood pressure of 10 mmHg (2–18) (P = 0.019) (mean ± ± SE) from 148 ± 3 to 138 ± 5 mmHg, and a mean reduction in GFR of 5 ml · min-1 · 1.73 m-2 (0.1–9) (P = 0.045).

CONCLUSIONS—Dual blockade of the RAS reduces albuminuria and blood pressure in type 2 diabetic patients with DN responding insufficiently to previous antihypertensive therapy, including ACE inhibitors in recommended doses.

Abbreviations: CALM, Candesartan and Lisinopril Microalbuminuria Study • DN, diabetic nephropathy • GFR, glomerular filtration rate • {theta}Alb, fractional clearance of albumin • {theta}IgG, fractional clearance of IgG • RAS, renin-angiotensin system • UKPDS, U.K. Prospective Diabetes Study


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 ANN INTERN MEDHome page
R. Kunz, C. Friedrich, M. Wolbers, and J. F.E. Mann
Meta-analysis: Effect of Monotherapy and Combination Therapy with Inhibitors of the Renin-Angiotensin System on Proteinuria in Renal Disease
Ann Intern Med, January 1, 2008; 148(1): 30 - 48.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
C. Berry, J.-C. Tardif, and M. G. Bourassa
Coronary Heart Disease in Patients With Diabetes: Part I: Recent Advances in Prevention and Noninvasive Management
J. Am. Coll. Cardiol., February 13, 2007; 49(6): 631 - 642.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
K. A. Griffin and A. K. Bidani
Progression of Renal Disease: Renoprotective Specificity of Renin-Angiotensin System Blockade
Clin. J. Am. Soc. Nephrol., September 1, 2006; 1(5): 1054 - 1065.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
Y. Kanno, T. Takenaka, T. Nakamura, and H. Suzuki
Add-On Angiotensin Receptor Blocker in Patients Who Have Proteinuric Chronic Kidney Diseases and Are Treated with Angiotensin-Converting Enzyme Inhibitors
Clin. J. Am. Soc. Nephrol., July 1, 2006; 1(4): 730 - 737.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
G. Remuzzi, M. Macia, and P. Ruggenenti
Prevention and Treatment of Diabetic Renal Disease in Type 2 Diabetes: The BENEDICT Study
J. Am. Soc. Nephrol., April 1, 2006; 17(4_suppl_2): S90 - S97.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
J. H. Song, S. H. Cha, H. J. Lee, S. W. Lee, G. H. Park, S. W. Lee, and M.-J. Kim
Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-{beta} in type 2 diabetic patients with advanced kidney disease
Nephrol. Dial. Transplant., March 1, 2006; 21(3): 683 - 689.
[Abstract] [Full Text] [PDF]

Home page
 British Journal of Diabetes & Vascular DiseaseHome page
P. De, G. Das, K. Harley, and H. Nair
Review: Dual blockade of renin-angiotensin system in diabetic nephropathy: review of literature and local experience
The British Journal of Diabetes & Vascular Disease, January 1, 2006; 6(1): 23 - 28.
[Abstract] [PDF]

Home page
 Eur Heart JHome page
R. M.A. van de Wal, D. J. van Veldhuisen, W. H. van Gilst, and A. A. Voors
Addition of an angiotensin receptor blocker to full-dose ACE-inhibition: controversial or common sense?
Eur. Heart J., November 2, 2005; 26(22): 2361 - 2367.
[Abstract] [Full Text] [PDF]

Home page
 British Journal of Diabetes & Vascular DiseaseHome page
R. Kumar and P. H Winocour
Review: Dual blockade of the renin angiotensin system in diabetes -- rationale and risks
The British Journal of Diabetes & Vascular Disease, September 1, 2005; 5(5): 266 - 271.
[Abstract] [PDF]

Home page
 Diabetes CareHome page
K. Rossing, K. J. Schjoedt, U. M. Smidt, F. Boomsma, and H.-H. Parving
Beneficial Effects of Adding Spironolactone to Recommended Antihypertensive Treatment in Diabetic Nephropathy: A randomized, double-masked, cross-over study
Diabetes Care, September 1, 2005; 28(9): 2106 - 2112.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Renin-Angiotensin-Aldosterone SystemHome page
P. K. Jacobsen
Review: Preventing End-Stage Renal Disease in Diabetic Patients -- Dual Blockade of the Renin-Angiotensin System (Part II)
Journal of Renin-Angiotensin-Aldosterone System, June 1, 2005; 6(2): 55 - 68.
[Abstract] [PDF]

Home page
 HypertensionHome page
T. W.R. Doulton, F. J. He, and G. A. MacGregor
Systematic Review of Combined Angiotensin-Converting Enzyme Inhibition and Angiotensin Receptor Blockade in Hypertension
Hypertension, May 1, 2005; 45(5): 880 - 886.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
M. J. Krimholtz, J. Karalliedde, S. Thomas, R. Bilous, and G. Viberti
Targeting Albumin Excretion Rate in the Treatment of the Hypertensive Diabetic Patient with Renal Disease
J. Am. Soc. Nephrol., March 1, 2005; 16(3_suppl_1): S42 - S47.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
N. H. Andersen, Per. L Poulsen, S. T. Knudsen, S. H. Poulsen, H. Eiskjaer, K. W. Hansen, K. Helleberg, and C. E. Mogensen
Long-Term Dual Blockade With Candesartan and Lisinopril in Hypertensive Patients With Diabetes: The CALM II study
Diabetes Care, February 1, 2005; 28(2): 273 - 277.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
V. L.M. Esnault, A. Ekhlas, C. Delcroix, M.-G. Moutel, and J.-M. Nguyen
Diuretic and Enhanced Sodium Restriction Results in Improved Antiproteinuric Response to RAS Blocking Agents
J. Am. Soc. Nephrol., February 1, 2005; 16(2): 474 - 481.
[Abstract] [Full Text] [PDF]

Home page
 Postgrad. Med. J.Home page
S M Marshall
Recent advances in diabetic nephropathy
Postgrad. Med. J., November 1, 2004; 80(949): 624 - 633.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
V. L Wade and B. L Gleason
Dual Blockade of the Renin-Angiotensin System in Diabetic Nephropathy
Ann. Pharmacother., July 1, 2004; 38(7): 1278 - 1282.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
M. Azizi and J. Menard
Combined Blockade of the Renin-Angiotensin System With Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Type 1 Receptor Antagonists
Circulation, June 1, 2004; 109(21): 2492 - 2499.
[Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
G. Deferrari, M. Ravera, V. Berruti, G. Leoncini, and L. Deferrari
Optimizing Therapy in the Diabetic Patient with Renal Disease: Antihypertensive Treatment
J. Am. Soc. Nephrol., January 1, 2004; 15(90010): S6 - 11.
[Abstract] [Full Text]

Home page
 Diabetes CareHome page
K. Rossing, P. Jacobsen, L. Pietraszek, and H.-H. Parving
Renoprotective Effects of Adding Angiotensin II Receptor Blocker to Maximal Recommended Doses of ACE Inhibitor in Diabetic Nephropathy: A randomized double-blind crossover trial
Diabetes Care, August 1, 2003; 26(8): 2268 - 2274.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Renin-Angiotensin-Aldosterone SystemHome page
N. H Andersen, S. T Knudsen, P. L Poulsen, S. H Poulsen, K. Helleberg, H. Eiskjaer, K. W Hansen, T. Bek, and C. E Mogensen
Dual blockade with candesartan cilexetil and lisinopril in hypertensive patients with diabetes mellitus: rationale and design
Journal of Renin-Angiotensin-Aldosterone System, June 1, 2003; 4(2): 96 - 99.
[Abstract] [PDF]

Home page
 Diabetes CareHome page
J. W. Tomlinson, K. R. Owen, and C. F. Close
Treating Hypertension in Diabetic Nephropathy
Diabetes Care, June 1, 2003; 26(6): 1802 - 1805.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
P. M Finnegan and B. L Gleason
Combination ACE Inhibitors and Angiotensin II Receptor Blockers for Hypertension
Ann. Pharmacother., June 1, 2003; 37(6): 886 - 889.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
J. Deira, H. Diaz, and J. Grande
Complete Blockade of the Renin-Angiotensin System in Patients With Advanced Diabetic Nephropathy
Diabetes Care, May 1, 2003; 26(5): 1635 - 1636.
[Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
P. Jacobsen, S. Andersen, B. R. Jensen, and H.-H. Parving
Additive Effect of ACE Inhibition and Angiotensin II Receptor Blockade in Type I Diabetic Patients with Diabetic Nephropathy
J. Am. Soc. Nephrol., April 1, 2003; 14(4): 992 - 999.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
K. Rossing, P. K. Christensen, B. V. Hansen, B. Carstensen, and H.-H. Parving
Optimal Dose of Candesartan for Renoprotection in Type 2 Diabetic Patients With Nephropathy: A double-blind randomized cross-over study
Diabetes Care, January 1, 2003; 26(1): 150 - 155.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
R. C. Campbell, P. Ruggenenti, and G. Remuzzi
Halting the Progression of Chronic Nephropathy
J. Am. Soc. Nephrol., November 1, 2002; 13(90003): S190 - 195.
[Abstract] [Full Text]

Home page
 Journal of Renin-Angiotensin-Aldosterone SystemHome page
J. Davies and A. Struthers
Review: The potential benefits of aldosterone antagonism in Type 2 diabetes mellitus
Journal of Renin-Angiotensin-Aldosterone System, September 1, 2002; 3(3): 150 - 155.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2002 by the American Diabetes Association.